Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

Frontiers in Oncology ◽

10.3389/fonc.2019.00667 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 2

Author(s):

Mi Jeong Kwon ◽

Jeong Eon Lee ◽

Joon Jeong ◽

Sang Uk Woo ◽

Jinil Han ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Recurrence Score ◽

Risk Classification ◽

Oncotype Dx ◽

Asian Women ◽

Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement

Current Oncology ◽

10.3747/co.20.1316 ◽

2013 ◽

Vol 20 (1) ◽

Cited By ~ 14

Author(s):

K.I. Pritchard ◽

K.A. Gelmon ◽

D. Rayson ◽

L. Provencher ◽

Marc Webster ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Consensus Statement ◽

Inhibitor Therapy ◽

Hormone Receptor Positive

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Breast Diseases A Year Book Quarterly ◽

10.1016/s1043-321x(09)79195-7 ◽

2009 ◽

Vol 20 (1) ◽

pp. 94-95

Author(s):

Y.H. Chia ◽

C.X. Ma

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Controlled Trial ◽

Inhibitor Therapy ◽

Double Blind ◽

Hormone Receptor Positive

146P Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.08.427 ◽

2021 ◽

Vol 32 ◽

pp. S424

Author(s):

R. Mutai ◽

T. Barkan ◽

A. Moore ◽

M. Sarfaty ◽

S. Stemmer ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Recurrence Score ◽

Oncotype Dx ◽

Prognostic Impact ◽

Oncotype Dx Recurrence Score ◽

Low Expression

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer

Cancer Research and Treatment ◽

10.4143/crt.2018.357 ◽

2019 ◽

Vol 51 (3) ◽

pp. 1073-1085 ◽

Cited By ~ 5

Author(s):

Sae Byul Lee ◽

Junetae Kim ◽

Guiyun Sohn ◽

Jisun Kim ◽

Il Yong Chung ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Hormone Receptor ◽

Recurrence Score ◽

Oncotype Dx ◽

Human Epidermal Growth Factor ◽

Epidermal Growth ◽

Randomized, controlled phase II trial of exemestane compared with medroxyprogesterone after nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e11088 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e11088-e11088

Author(s):

T. Wang ◽

H. Huang ◽

S. Zhang ◽

L. Bian ◽

Z. Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Randomized Controlled ◽

Hormone Receptor Positive

88. Validity of Oncotype Dx recurrence score in predicting recurrence in hormone receptor positive and node negative early breast cancer patients

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2016.06.094 ◽

2016 ◽

Vol 42 (9) ◽

pp. S103

Author(s):

A. Munir ◽

S. Udyashankar ◽

D. Thomas ◽

G. Dazeley ◽

A. Huws ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Recurrence Score ◽

Oncotype Dx ◽

Breast Cancer Patients ◽

Node Negative ◽

Breast cancer specific survival in patients with node-positive hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.6575 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 6575-6575

Author(s):

Megan Roberts ◽

Valentina I. Petkov ◽

Dave P. Miller ◽

Steven Shak ◽

Nadia Howlader ◽

...

Keyword(s):

Breast Cancer ◽

Invasive Breast Cancer ◽

Hormone Receptor ◽

Recurrence Score ◽

Oncotype Dx ◽

Breast Cancer Specific Survival ◽

Seer Database ◽

Cancer Specific Survival ◽

Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come

Annals of Surgical Oncology ◽

10.1245/s10434-019-07240-y ◽

2019 ◽

Vol 26 (5) ◽

pp. 1173-1175 ◽

Cited By ~ 4

Author(s):

Elizabeth A. Mittendorf ◽

Tari A. King

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Recurrence Score ◽

Oncotype Dx ◽

Node Positive ◽

Evaluation of Prognosis in Hormone Receptor–Positive/HER2-Negative and Lymph Node–Negative Breast Cancer With Low Oncotype DX Recurrence Score

Clinical Breast Cancer ◽

10.1016/j.clbc.2017.12.006 ◽

2018 ◽

Vol 18 (5) ◽

pp. 347-352 ◽

Cited By ~ 2

Author(s):

Jane Meisel ◽

Chao Zhang ◽

Cameron Neely ◽

Pia Mendoza ◽

Shuo You ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Hormone Receptor ◽

Recurrence Score ◽

Oncotype Dx ◽

Node Negative ◽

Node Negative Breast Cancer ◽